ARA-290 — Research Overview
Chemical Name: Helix B surface peptide of erythropoietin (11-amino acid sequence) Also Known As: ARA290, pHBSP (peptide Helix B Surface Peptide) Structure: Synthetic 11-amino acid peptide modeled from the three-dimensional tertiary structure of Helix B of the erythropoietin molecule Target: Innate Repair Receptor (IRR) — a heteromeric complex formed by the erythropoietin receptor and the beta-common receptor (CD131) Regulatory Status: Granted FDA Orphan Drug designation for treatment of neuropathic pain in sarcoidosis patients Category: Non-erythropoietic tissue-protective and neuroprotective research peptide
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is ARA-290?
ARA-290 is a synthetic 11-amino acid peptide derived from the three-dimensional tertiary structure of erythropoietin (EPO) — specifically engineered from the Helix B surface region of the EPO molecule. Erythropoietin is a naturally occurring hormone primarily known for stimulating red blood cell production, but research over the past two decades has established that EPO also mediates significant tissue protection, anti-inflammatory, and neuroprotective effects through a separate receptor pathway that is distinct from its hematopoietic signaling.
The fundamental problem with using full-length erythropoietin for tissue protection research is that its hematopoietic effects — increased red blood cell production, elevated hematocrit, and associated cardiovascular risks including thrombosis — limit its clinical utility at doses required for tissue-protective effects. ARA-290 was engineered specifically to separate these two functions. By modeling the peptide from the tertiary structural domain responsible for innate repair receptor binding rather than the primary EPO receptor binding site, ARA-290 retains the tissue-protective and neuroprotective properties of EPO while eliminating erythropoietic activity entirely.
ARA-290 has been evaluated across a broad spectrum of preclinical models including diet-induced insulin resistance, diabetic retinopathy, diabetic autonomic neuropathy, myocardial infarction, chronic heart failure, traumatic brain injury, neuropathic pain, and inflammatory conditions. It has also been evaluated in published human clinical trials in patients with sarcoidosis-associated small fiber neuropathy and type 2 diabetes with neuropathy. The FDA granted ARA-290 Orphan Drug designation for treatment of neuropathic pain in sarcoidosis patients, reflecting the significance of its clinical development program.
Mechanism of Action
ARA-290 exerts its effects by selectively activating the innate repair receptor (IRR) — a heteromeric complex formed by the erythropoietin receptor monomer and the beta-common receptor (also known as CD131). This receptor complex is distinct from the homodimeric erythropoietin receptor that drives red blood cell production. The IRR becomes locally upregulated at sites of tissue injury and stress, and its activation initiates a coordinated cellular protective response.
Activation of the IRR by ARA-290 triggers several downstream effects that have been characterized across preclinical research.
Anti-inflammatory signaling: ARA-290 suppresses the neurogenic inflammatory response following nerve injury. Spinal microglia and astrocyte activation — which drive and maintain neuropathic pain states — is reduced in a dose-dependent manner following ARA-290 treatment. Inflammatory cytokines including TNF-alpha and interleukin-1 beta are reduced at spinal cord and supraspinal sites.
Anti-apoptotic protection: IRR activation initiates local inhibition of death signaling pathways, reducing apoptotic cell death in injured neural and other tissues.
Small nerve fiber repair: ARA-290 has been shown to support the regrowth and density recovery of intraepidermal nerve fibers — the small unmyelinated C and lightly myelinated A-delta fibers of the sensory and autonomic peripheral nervous system — in both preclinical neuropathy models and published human clinical studies.
Metabolic effects: In models of insulin resistance and type 2 diabetes, IRR activation by ARA-290 has been associated with improvements in glycemic control and lipid metabolism, independent of its neural effects.
No erythropoietic activity: Unlike full-length EPO, ARA-290 does not stimulate red blood cell production, does not elevate hematocrit, and has not been associated with the cardiovascular risks including thrombosis that limit clinical use of erythropoietin.
Published Research
Study 1 — Foundational Neuropathic Pain Study: Long-Term Allodynia Relief in Rats and Knockout Mice
Authors: Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A Year: 2011 Journal: Anesthesiology PMID: 21873879 Full text: https://pubmed.ncbi.nlm.nih.gov/21873879/
This foundational preclinical study established ARA-290’s mechanism of action in neuropathic pain through the beta-common receptor. Rats and beta-common receptor knockout mice underwent spared nerve injury and were then treated with ARA-290 or vehicle using five subcutaneous injections at two-day intervals followed by once weekly treatment.
In rats ARA-290 produced effective long-term relief of both tactile and cold allodynia — pain hypersensitivity responses — lasting as long as 15 weeks of observation regardless of whether treatment was continued or stopped after the initial five-dose period.
In beta-common receptor knockout mice ARA-290 produced no pain relief, directly confirming that the beta-common receptor is the essential mediator of ARA-290’s analgesic effects.
The authors concluded that ARA-290 produces long-term relief of allodynia through beta-common receptor activation and that its antiinflammatory properties within the central nervous system are likely responsible for the sustained effect. They noted that because ARA-290, in contrast to erythropoietin, is devoid of hematopoietic and cardiovascular side effects, it represents a promising candidate for further development in peripheral nerve injury-induced neuropathic pain.
Study 2 — Dose-Response Study: Spinal Microglia Suppression and Neuropathic Pain
Authors: Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, Cerami A, Dahan A Year: 2014 Journal: Molecular Pain PMID: 24529189 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC3928087/
This study characterized the dose-response relationship of ARA-290 on both allodynia and concurrent spinal cord microglia and astrocyte activity in rats following spared nerve injury. Animals received one of four doses of ARA-290 (3, 10, 30, or 60 micrograms per kilogram) or vehicle on days 1, 3, 6, 8, and 10 post-surgery.
ARA-290 reduced allodynia in a dose-dependent manner, with statistically significant relief at 30 and 60 microgram per kilogram doses.
Suppression of spinal microglia activation was observed concurrent with pain relief, suggesting a mechanistic link between ARA-290’s suppression of central neuroinflammation and its analgesic effect.
The relationship between microglial suppression and pain relief was dose-correlated, supporting the central anti-inflammatory mechanism as the primary driver of the observed analgesic effect.
The authors concluded that ARA-290 dose-dependently reduces allodynia coupled to suppression of the spinal microglia response, supporting the mechanistic link between central inflammation suppression and neuropathic pain relief.
Study 3 — Human Clinical Trial: Sarcoidosis-Associated Small Fiber Neuropathy
Authors: Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M Year: 2013 Journal: Molecular Medicine Full text: https://link.springer.com/article/10.2119/molmed.2013.00122
This was a blinded placebo-controlled human clinical trial evaluating ARA-290 in patients with sarcoidosis-associated small nerve fiber loss and damage — a condition characterized by loss of the small unmyelinated and lightly myelinated fibers of the sensory and autonomic peripheral nervous system producing pain, numbness, dysesthesia, and autonomic dysfunction. Patients received daily subcutaneous administration of ARA-290 for 28 days.
28 days of daily subcutaneous ARA-290 significantly improved neuropathic symptoms in patients with documented small nerve fiber loss compared to placebo.
Corneal nerve fiber density — a measurable objective marker of small nerve fiber health assessed by corneal confocal microscopy — increased in ARA-290-treated patients, providing objective evidence of nerve fiber regrowth alongside subjective symptom improvement.
The compound was well tolerated with no significant safety issues identified during the study period.
This was one of the first published human clinical demonstrations that a non-erythropoietic EPO-derived peptide could produce measurable improvements in both symptoms and objective nerve fiber density in patients with peripheral neuropathy.
Study 4 — Human Clinical Trial: Type 2 Diabetes and Neuropathic Symptoms
Authors: Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A Year: 2014 Journal: Molecular Medicine PMCID: PMC4365069 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/
This Phase 2 human clinical study evaluated ARA-290 in patients with type 2 diabetes and painful neuropathy. ARA-290 at 4 mg or placebo was self-administered subcutaneously daily for 28 days, with subjects followed for an additional month without treatment.
No potential safety issues were identified across the study period.
Subjects receiving ARA-290 exhibited improvements in HbA1c and lipid profiles throughout the 56-day observation period, including during the post-treatment follow-up month, suggesting durable metabolic effects beyond the active treatment window.
Neuropathic symptom improvements were observed in the ARA-290 group consistent with findings from the sarcoidosis trial.
The study authors noted that ARA-290 has demonstrated efficacy across preclinical and clinical studies of metabolic control and neuropathy, and that its selectivity for the innate repair receptor without hematopoietic activity addresses a key limitation of full-length erythropoietin in this research space.
Study 5 — Cerebral Ischemia Neuroprotection: Stroke Animal Model
Authors: Published in PMC Year: 2024 Journal: PMC Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC10941562/
This preclinical study examined ARA-290’s neuroprotective effects in a middle cerebral artery occlusion (MCAO) mouse model of cerebral ischemic stroke — one of the most widely used experimental models for studying stroke pathophysiology. Male C57BL/6J mice underwent MCAO and reperfusion and received ARA-290 at the beginning of reperfusion.
ARA-290 exerted a qualitatively similar neuroprotective effect to full-length EPO following MCAO in terms of reducing brain infarction volume and improving neurological function scores.
ARA-290 reduced neuronal apoptosis as assessed by immunofluorescence staining.
Critically and unlike full-length EPO, ARA-290 did not induce splenomegaly or erythropoiesis, confirming its non-hematopoietic profile even at neuroprotective doses in this model.
Serum metabolomics profiling was performed alongside standard endpoints, adding mechanistic depth to the characterization of ARA-290’s effects in acute ischemic injury.
The authors identified the beta-common receptor as the mediating pathway for ARA-290’s neuroprotective effects in this model, consistent with findings from neuropathic pain research, and noted that further studies are needed to fully characterize the underlying mechanisms in cerebral ischemia specifically.
Current Research Status
ARA-290 has one of the more developed clinical research profiles among the compounds in the peptide research space, with published Phase 2 human clinical trial data in both sarcoidosis-associated neuropathy and type 2 diabetes with neuropathy. It has received FDA Orphan Drug designation for treatment of neuropathic pain in sarcoidosis — a formal regulatory recognition that reflects the compound’s potential to address an unmet medical need.
ARA-290 is not FDA-approved for any indication and has not completed Phase 3 clinical trials. Orphan Drug designation is a development designation and does not constitute approval. Phase 3 trials would be required before any regulatory approval pathway could be established.
The following areas remain active subjects of ongoing research or require further investigation:
Phase 3 clinical trial data in neuropathy indications.
Long-term safety profile beyond the published 28 to 56 day clinical trial observation windows.
Efficacy across broader neuropathy populations beyond sarcoidosis and type 2 diabetes.
Mechanisms underlying the sustained post-treatment metabolic effects observed in the Type 2 diabetes trial.
Optimal dosing protocols for different research applications across the range of studied disease models.
Reconstitution Note
ARA-290 is a synthetic peptide compound. Bacteriostatic water is the standard reconstitution solvent for this class of compound in laboratory research settings. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the ARA-290 product page: https://roguecompounds.com/product/ara-290/